U.S. Markets closed

These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

ALLISON GATLIN
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

Gilead Sciences should acquire Celgene's psoriasis drug Otezla, but only for less than $9.6 billion, analysts said Thursday. Celgene is divesting Otezla ahead of its Bristol-Myers merger.